The company's lead therapy fared well in a phase 2a trial to treat two separate conditions.
Pliant Therapeutics, Inc. (PLRX) delivered earnings and revenue surprises of -1.52% and 31.87%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?...
Cardiff Oncology (CRDF) delivered earnings and revenue surprises of -8.70% and 10.67%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
Pliant Therapeutics, Inc. (PLRX) delivered earnings and revenue surprises of -2.86% and 27.10%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?...
Codexis (CDXS) delivered earnings and revenue surprises of 17.39% and 4.30%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
Techne (TECH) delivered earnings and revenue surprises of -4.08% and 6.34%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
The company's experimental idiopathic pulmonary fibrosis drug is showing a lot of promise.
Updates from bluebird (BLUE) and Catalyst Pharmaceuticals (CPRX) are the key highlights from the biotech sector during the past week.
Shares of Pliant Therapeutics (PLRX) have been rising since management reported positive interim data from a mid-stage study evaluating a higher dose of its lead pipeline candidate in IPF patients.
Pliant Therapeutics zoomed 34% higher and added to that gain in the next session.This followed good news about clinical trials for a lung-condition treatment.